Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea · Delayed Price · Currency is KRW 1,912.00
+441.00 (29.98%)
Feb 5, 2026, 3:30 PM KST
Xcell Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,362 | 1,934 | 1,124 | 1,020 | 1,966 | 540.2 |
Other Revenue | - | - | - | 0 | - | - |
| 1,362 | 1,934 | 1,124 | 1,020 | 1,966 | 540.2 | |
Revenue Growth (YoY) | -29.97% | 72.11% | 10.18% | -48.12% | 264.00% | 531.11% |
Cost of Revenue | 2,874 | 3,333 | 2,987 | 2,773 | 2,284 | 1,641 |
Gross Profit | -1,512 | -1,399 | -1,863 | -1,753 | -318.08 | -1,101 |
Selling, General & Admin | 5,100 | 4,323 | 3,400 | 3,219 | 3,058 | 1,819 |
Research & Development | 2,417 | 2,728 | 2,753 | 2,596 | 1,832 | 1,166 |
Amortization of Goodwill & Intangibles | 103.56 | 53.23 | 53.83 | 73.48 | 56.2 | 39.27 |
Other Operating Expenses | 28.56 | 36.01 | 71.45 | 140.21 | 78.1 | 4.63 |
Operating Expenses | 8,583 | 7,931 | 7,076 | 6,546 | 5,387 | 3,376 |
Operating Income | -10,095 | -9,330 | -8,939 | -8,299 | -5,705 | -4,477 |
Interest Expense | - | -4.4 | -3.12 | -2.89 | -179.78 | -827.41 |
Interest & Investment Income | 242.13 | 201.29 | 50.84 | 114.02 | 41.75 | 15.12 |
Currency Exchange Gain (Loss) | 5.72 | 12.84 | 2.52 | 11.57 | 2.38 | -0.23 |
Other Non Operating Income (Expenses) | -256.34 | -295.6 | -257.58 | -165.59 | -3,186 | -4,838 |
EBT Excluding Unusual Items | -10,104 | -9,416 | -9,147 | -8,342 | -9,026 | -10,127 |
Gain (Loss) on Sale of Investments | 9.43 | 2.72 | -0.87 | - | - | - |
Gain (Loss) on Sale of Assets | 85.09 | -130.13 | 21 | -0.53 | -12 | 3 |
Asset Writedown | - | - | -154.12 | - | - | - |
Pretax Income | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 |
Net Income | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 |
Net Income to Common | -10,010 | -9,543 | -9,281 | -8,342 | -9,038 | -10,124 |
Shares Outstanding (Basic) | 11 | 10 | 9 | 9 | 8 | 2 |
Shares Outstanding (Diluted) | 11 | 10 | 9 | 9 | 8 | 2 |
Shares Change (YoY) | 14.60% | 13.14% | 1.02% | 5.71% | 364.87% | 3.12% |
EPS (Basic) | -915.09 | -953.76 | -1049.40 | -952.90 | -1091.40 | -5683.16 |
EPS (Diluted) | -915.30 | -954.00 | -1049.40 | -953.00 | -1091.40 | -5683.16 |
Free Cash Flow | -9,273 | -7,379 | -7,008 | -8,475 | -5,952 | -5,657 |
Free Cash Flow Per Share | -847.76 | -737.48 | -792.48 | -968.02 | -718.67 | -3175.38 |
Gross Margin | -110.99% | -72.30% | -165.77% | -171.89% | -16.18% | -203.76% |
Operating Margin | -741.13% | -482.33% | -795.37% | -813.59% | -290.14% | -828.78% |
Profit Margin | -734.84% | -493.36% | -825.74% | -817.85% | -459.67% | -1874.20% |
Free Cash Flow Margin | -680.78% | -381.48% | -623.58% | -830.82% | -302.69% | -1047.18% |
EBITDA | -8,385 | -7,677 | -7,341 | -6,786 | -4,686 | -3,795 |
EBITDA Margin | - | - | - | - | -238.34% | - |
D&A For EBITDA | 1,710 | 1,653 | 1,598 | 1,513 | 1,019 | 681.79 |
EBIT | -10,095 | -9,330 | -8,939 | -8,299 | -5,705 | -4,477 |
EBIT Margin | - | - | - | - | -290.14% | - |
Advertising Expenses | - | 154.72 | 315.24 | 267.87 | 279.25 | 97.97 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.